Lassa Fever (Experimental)
Lassa Fever — Experimental Vaccine Candidates
Platform: Pathogen — No Licensed Vaccine
Rodent-borne arenavirus causing Lassa fever, endemic in West Africa — vaccine candidates are in Phase 2 trials with no licensed product.
EXPERIMENTAL — No licensed vaccine or therapeutic currently approved.
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Wikipedia Overview
Full article ↗
Lassa fever, also known as Lassa hemorrhagic fever, is a type of viral hemorrhagic fever caused by the Lassa virus. Many of those infected by the virus do not develop symptoms. When symptoms occur, they typically include fever, weakness, headaches, vomiting, and muscle pains. Less commonly there may be bleeding from the mouth or gastrointestinal tract. The risk of death once infected is about one percent and frequently occurs within two weeks of the onset of symptoms. Of those who survive, about a quarter have hearing loss, which improves within three months in about half of these cases.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗No Semantic Scholar results retrieved.